|
|
|
Apyx Medical Corp (NASDAQ: APYX) |
|
|
|
| |
Apyx Medical Corp Outlook |
On November 8 2024 the Apyx Medical Corp provided following guidance
nnApyx Medical Corporation Announces Third Quarter 2024 Financial Performance; Revises 2024 Financial Projections and Unveils 2025 Financial Outlooknn
nnCLEARWATER, Fla., Nov. 8, 2024nn – nApyx Medical Corporation (NASDAQ: APYX)n, renowned for its innovative helium plasma and radiofrequency technology branded as Renuvion, has released its financial results for the third quarter ending September 30, 2024. In addition, the company has provided an update on its financial forecasts for the full year ending December 31, 2024, and has introduced preliminary expectations for the fiscal year ending December 31, 2025.
While the company has clarified its updated financial guidance, the detailed numerical projections for both 2024 and 2025 have not been specified in the communicated report. Apyx Medical remains focused on advancing its technology and enhancing shareholder value through strategic initiatives.
For further information regarding Apyx Medical’s performance and future outlook, stakeholders are encouraged to stay tuned for more comprehensive reports and disclosures in the upcoming months.,
|
On March 21 2024 the Apyx Medical Corp provided following guidance
Apyx Medical Corporation, a leading provider of innovative medical technologies including its proprietary helium plasma and radiofrequency technology under the brand name Renuvion, announced its financial results for the fourth quarter and full year of 2023. The Company reported a total revenue of $14.7 million, marking a 16% increase compared to the previous year.
Furthermore, Apyx Medical introduced its financial outlook for the full year ending December 31, 2024. The Company is optimistic about its growth prospects and is forecasting strong performance in the upcoming year. With a track record of success and a commitment to innovation, Apyx Medical is well-positioned to continue its upward trajectory in the medical technology industry.
Investors and stakeholders can look forward to continued success and value creation from Apyx Medical Corporation as it looks ahead to a promising future in 2024 and beyond.
|
On November 9 2023 the Apyx Medical Corp provided following guidance
Apyx Medical Corporation, a leading manufacturer of proprietary helium plasma and radiofrequency technology known as Renuvion, announced its financial results for the third quarter of 2023. The company reported a total revenue of $12.0 million, which represents a significant increase of 31% compared to the same period last year. Within this revenue, the Advanced Energy division contributed $9.8 million.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
